Therapeutic efficacy of cardiosphere-derived cells in a transgenic mouse model of non-ischaemic dilated...

Area of Science:

• Cardiology
• Regenerative Medicine
• Cell Therapy

Background:

• Cardiosphere-derived cells (CDCs) demonstrate regenerative potential post-myocardial infarction.
• The efficacy of CDCs in non-ischaemic dilated cardiomyopathy (DCM) remains largely uninvestigated.

Purpose of the Study:

• To evaluate the therapeutic effects of CDC transplantation in a Gαq-induced mouse model of DCM.
• To determine if CDCs can mitigate cardiac dysfunction and improve survival in non-ischaemic heart failure.

Main Methods:

• Intramyocardial injection of wild-type mouse CDCs or vehicle into Gαq mice at different ages.
• Assessment of cardiac function, ventricular remodelling, oxidative stress, inflammation, and survival over 3 months.
• Evaluation of cell engraftment to understand the mechanism of action.

Main Results:

• Vehicle-treated Gαq mice exhibited progressive cardiac deterioration, oxidative stress, inflammation, and adverse remodelling.
• CDC transplantation preserved cardiac function and volumes, enhanced survival, and promoted cardiomyogenesis.
• Gαq-induced oxidative stress and inflammation were significantly blunted in CDC-treated mice.
• Transplanted cell engraftment was minimal, suggesting an indirect mechanism of benefit.

Conclusions:

• Cardiosphere-derived cells effectively reverse key cellular abnormalities and prevent adverse remodelling in a preclinical model of DCM.
• CDC therapy demonstrates significant potential for improving outcomes in non-ischaemic heart failure.
• The indirect mechanism of action opens new therapeutic avenues for CDC applications in heart failure.